Statement on Centers for Medicare and Medicaid Services Proposed Rule on Obesity Coverage
Genetically Targeted Technologies and the MINI Act
PACH One-Pager
Genetically Targeted Technologies: A Big Win for Heart Patients
PACH Infographic
A “MINI” Act Could Be Big for Patients
Health Policy Today Blog
Overview and Outlook for RNA-Based Therapies
Avalere Study
Coverage for Obesity Treatment CMS Letter
IRA Drug Price Negotiation Impact on Cardiovascular Drugs
Avalere Study
Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives
A group of health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. Doing so, the group says, could mitigate the detrimental outcomes and comorbidities that often develop as a result of obesity, a disease that places significant burdens on individuals and the health care system.
Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the US Inflation Reduction Act
Article Published on the Journal of Medical Economics
Obesity
Pressure’s Mounting: The Urgent Need for Innovation in Hypertension Care
For Some, Step Therapy Is a Matter of Death or Life
POLL: HEALTH PLAN DELAYS ARE “UNREASONABLE,” DANGEROUS FOR HEART PATIENTS
It’s Time for Congress to Finally Treat Obesity Like the Epidemic It Is
State Leaders Tackle Obesity
Why Employers Should Invest in Obesity Treatment
Medicare Part D Extends Coverage of Obesity Treatments for New Indication
A MINI Act Could Be Big for Heart Patients
A “MINI” Act Could Be Big for Patients
Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives
A group of health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. Doing so, the group says, could mitigate the detrimental outcomes and comorbidities that often develop as a result of obesity, a disease that places significant burdens on individuals and the health care system.
IRA Drug Price Negotiation Impact on Cardiovascular Drugs
Avalere Study
